$0.7501
-0.12-14%
At close: Nov 12, 4:00 PM EST
OS Therapies Inc
OSTXAMEX
OS Therapies fell 58.8% from $1.82 to $0.75, behind the S&P 500's +12.7%. Its worst day was Jun 30 (−15.2%), and its low came Nov 12 at $0.75.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.21 missed the $-0.13 estimate on $0.00 revenue (est. $27.5M).
−5.0% · S&P 500 −0.9%
EPS of $-0.41 missed the $-0.16 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
+6.0% · S&P 500 +2.9%
OS Therapies shares rose 22.1%, while the S&P 500 rose 0.8%.
+22.1%, the year's best day · S&P 500 +0.8%
EPS of $-0.27 missed the $-0.19 estimate on $0.00 revenue (est. $242,750.00).
−8.0% · S&P 500 −0.1%
OS Therapies shares fell 12.6%, while the S&P 500 rose 0.3%.
−12.6% · S&P 500 +0.3%
OS Therapies shares rose 12.2%, while the S&P 500 rose 1.0%.
+12.2% · S&P 500 +1.0%
OS Therapies closed at its highest level of the year, 23.1% above where the year started.
+19.1% · S&P 500 +1.6%
OS Therapies shares rose 17.8%, while the S&P 500 rose 0.8%.
+17.8% · S&P 500 +0.8%
EPS of $-0.20 beat the $-0.23 estimate on $0.00 revenue (est. $204,400.00).
−9.3% · S&P 500 −0.5%
Leading Clinical Stage Oncology Company Now Able to Complete CMMA Submission to U.K’s MHRA for Early Commercial Access and Trial Authorisation
−14.8% · S&P 500 −4.4%
Where it ended: a close of $0.75 on Nov 12, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.12, revenue est. $600,000.00).
Nothing in the past 12 months.
All OSTX dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for OSTX and SPY from Benzinga historical bars. Not investment advice.
